Autologous formalin-fixed tumor vaccine suppressed re-recurrence of HCV-related hepatocellular carcinoma following 29 unsuccessful treatments with extensive conventional therapy: a case report

World Journal of Surgical Oncology

Tadao Ohno²  Toshio Inui¹ 

[1] Inui Cancer Immunotherapy Clinic, 6-14-17 Kinndachou, Moriguchi-shi, Osaka, 570-0011, Japan;Advanced Research Institute for Science and Engineering, Waseda University, 3-4-1 Okubo, Shinjuku-ku, Tokyo, 169-8555, Japan

关键词: suppression of re-recurrence;    hepatocellular carcinoma;    Tumor vaccine;   

Others  :  827508
DOI  :  10.1186/1477-7819-10-144

 received in 2012-04-06, accepted in 2012-07-12,  发布年份 2012

【 摘 要 】

Treatment of hepatocellular carcinoma (HCC) with autologous formalin-fixed tumor vaccine after primary resection has been shown to suppress the recurrence of hepatitis B virus-associated HCC, but the effect of this treatment on hepatitis C virus (HCV)-related disease has not yet been clarified. Here, we report a case of a patient with repeat recurrent HCC that was associated with HCV who had endured 29 episodes of HCC recurrence despite a variety of therapy using conventional methods. Finally, treatment with a single course of autologous formalin-fixed tumor vaccine resulted in suppression of potential further re-recurrence of HCC for more than 43 months without any additional treatment.

【 授权许可】

   
2012 Inui and Ohno; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Kuang M, Peng BG, Lu MD, Liang LJ, Huang JF, He Q, Hua YP, Totsuka S, Liu SQ, Leong KW, Ohno T: Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res 2004, 10:1574-1579.
• [2]Nagano H, Monden M: FAIT (FU arterial infusion and interferon therapy) for hepatocellular carcinoma. Nihon Rinsho 2006, 64:1314-1318.
• [3]Nagano H, Miyamoto A, Wada H, Ota H, Marubashi S, Takeda Y, Dono K, Umeshita K, Sakon M, Monden M: Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules. Cancer 2007, 110:2493-2501.
• [4]Wada H, Nagano H, Noda T, Damdinsuren B, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Dono K, Sakon M, Wakasa K, Monden M: Complete remission of hepatocellular carcinoma with portal vein tumor thrombus and lymph node metastases by arterial infusion of 5-fluorouracil and interferon-alpha combination therapy following hepatic resection. J Gastroenterol 2007, 42:501-506.
• [5]Ishikawa E, Tsuboi K, Yamamoto T, Muroi A, Enomoto T, Takano S, Matsumura A, Ohno T: A clinical trial of autologous formalin-fixed tumor vaccine for glioblastoma multiforme patients. Cancer Sci 2007, 98:1226-1233.
• [6]Ikeda K, Kobayashi M, Saitoh S, Someya T, Hosaka T, Akuta N, Suzuki F, Tsubota A, Suzuki Y, Arase Y, Kumada H: Recurrence rate and prognosis of patients with hepatocellular carcinoma that developed after elimination of hepatitis C virus RNA by interferon therapy. A closed cohort study including matched control patients. Oncology 2003, 65:204-210.